Author: openjargon

The Ingenia Communities Ltd (ASX: INA) share price is in focus after the company rejected a revised takeover proposal, stating it undervalues the business. Warburg Pincus increased its non-binding indicative offer to $5.05 cash per stapled security, up from $4.75, but Ingenia’s board concluded the proposal is not in the best interests of its securityholders.

What did Ingenia Communities report?

• Received a revised, non-binding indicative takeover offer at $5.05 per stapled security
• Offer followed a prior bid at $4.75 per security
• Ingenia Board, supported by independent financial and legal advice, rejected the new proposal
• The proposal was conditional on due diligence and regulatory approvals
• Ingenia’s market capitalisation stands at approximately $1.7 billion

What else do investors need to know?

Ingenia’s board engaged financial adviser Greenhill, a Mizuho affiliate, and external legal counsel, showing its commitment to a careful and thorough assessment of offers. The board remains open to alternative proposals that offer compelling value and serve the best interests of securityholders.

The company continues to focus on delivering its strategic plan. Securityholders are advised that no action is required regarding the revised offer and Ingenia remains committed to growth through acquisition and development.

What’s next for Ingenia Communities?

Ingenia will keep executing its current strategy, which aims to deliver long-term value for securityholders. The board indicated confidence in the company’s direction and growth path, and will continue to consider any future proposals that adequately reflect Ingenia’s value.

The company operates 96 communities and has a strong platform for ongoing expansion, focused on Australia’s growing seniors’ market.

Ingenia Communities share price snapshot

Over the past 12 months, Ingenia shares have declined 22%, trailing the S&P/ASX 200 Index (ASX: XJO), which has declined 1% over the same period.

View Original Announcement

The post Ingenia Communities rejects revised $5.05 takeover offer appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today
• Why are Ingenia shares soaring today?
• Ingenia Communities Group rejects takeover offer, backs growth strategy
• Ingenia Communities proposes to acquire Peet, boosting growth

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

CSL Ltd (ASX: CSL) shares have clawed back serious ground in recent months, climbing 10% over the past month and 29% over the past six months. Even so, the ASX biotech stock remains 12% below where it stood a year ago.

The next test looms larger, though: the psychological $200 barrier. Clearing it won’t be a gimme. The $85 billion healthcare giant still has to prove it can deliver on several fronts before that milestone becomes more than just a broker’s spreadsheet fantasy.

The good news? CSL has actually laid out the roadmap. Now it just has to walk it.

The Behring problem, and the Behring fix

Everything starts with CSL Behring, by far the group’s biggest business and the one that’s caused the most headaches. After a rough patch, management is now promising a return to mid-single-digit revenue growth in FY27, with immunoglobulin sales expected to climb at a mid-to-high single-digit clip.

That’s not just corporate optimism. Demand for immunoglobulin remains genuinely strong, and CSL is squeezing more out of its plasma collection and manufacturing process at the same time. If Behring turns the corner, it drags the whole group with it.

New kids on the block

CSL isn’t relying on Behring alone. ANDEMBRY and HEMGENIX both posted strong uptake in FY26, and management expects that momentum to keep building.

If these newer therapies can scale into genuine earnings contributors, they give CSL something it’s lacked for a while: a growth story that doesn’t depend entirely on plasma.

Cost-cutting isn’t just noise

CSL’s transformation program has actual receipts. The company banked around US$176 million in cost savings during FY26 – ahead of schedule – with more coming in FY27. Roughly half of those incremental savings are being ploughed straight back into growth initiatives.

If revenue growth and cost discipline both fire at once, that’s a genuine earnings tailwind, not just a management slide deck promise.

The part nobody wants to talk about

Here’s the catch. CSL expects Vifor revenue to fall roughly 25% in FY27, hammered by generic competition in iron products. Seqirus, meanwhile, is only expected to scrape out low-single-digit growth.

Translation: Behring and the new therapies need to do the heavy lifting almost entirely on their own, while the rest of the portfolio does its best impression of dead weight.

Brokers are starting to bite

That improving – if uneven – outlook is enough to get some brokers genuinely excited. In September, RBC Capital Markets upgraded CSL to outperform and hiked its price target from $148 all the way to $213. That points to a 21% upside at the current share price level.

RBC’s bullish call rests on a simple bet: that Behring’s recovery can outrun the drag from Vifor and Seqirus, and earnings growth returns from here.

Barrenjoey followed with an upgrade to overweight and a $180 target.

Not everyone’s convinced. Citi is stuck at hold with a $160 target, while UBS sits at buy with $181.

Foolish takeaway

The path to $200 isn’t a straight line. It’s a bet that demand for immunoglobulins stays strong, new therapies scale quickly, cost savings keep flowing, and the weak links stop bleeding.

Leadership uncertainty adds another variable to the $200 case. In a notice of annual general meeting lodged with the ASX last week, CSL chair Brian McNamee said the search for a new Chief Executive Officer was well-advanced, though still ongoing.

Investors will want clarity on who’s steering the recovery before fully buying into it.

That’s a lot of boxes to tick. But if CSL ticks them, $200 starts looking like the obvious next stop.

The post Why brokers think CSL shares could be on track for $200 appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Coles, NAB, CSL shares
• ASX 200 healthcare shares lead a weaker market amid 82% chance of a rate hike
• How much passive income could I make by investing $500 a month in ASX shares?
• Are BHP, CBA, and CSL shares top buys?
• 6 ASX 200 shares boosted by brokers this week

Citigroup is an advertising partner of Motley Fool Money. Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Share prices of many ASX shares have fallen recently due to worries about bond yields, private credit uncertainties, AI, the Middle East, inflation and rising interest rates. There’s a lot to worry about for investors.

With all of the above in mind, it’s not surprising that some interest rate-sensitive ASX shares are down (close) to their 52-week lows.

Below are two of my favourites right now at a low point.

Centuria Industrial REIT (ASX: CIP)

Interest rates act like gravity on property prices – when rates go down, interest costs fall, and property values are likely to rise. The reverse is also true. With interest rates anticipated to rise this year, the market has pushed the Centuria Industrial REIT share price down 20% in the past year to a 52-week low.

This business owns a portfolio of industrial properties across Australia. I think it’s appealing to be able to buy a slice of so many properties in just a single transaction.

Property values do change over time, and it’s hard to know exactly what the ASX share’s property portfolio is worth without actually going to sell it, which the business isn’t going to do.

However, we can look at the REIT’s distribution as a way to see how attractive it is.

The business grew its annual distribution by 3% in FY26 and expects to grow its payout by another 3% to 17.3 cents per unit. That’s a forward distribution yield of 6.1%. To me, that’s an excellent yield from a business like this.

When rates do eventually come down, I think this valuation could make it seem like a cheap ASX share.

JB Hi-Fi Ltd (ASX: JBH)

JB Hi-Fi is another name that has seen a sell-off. The JB Hi-Fi share price has dropped 44% in the past year, and it’s now close to its 52-week low.

Inflation of living costs and higher interest rates are already causing headwinds, and investors are feeling negative. I think it’s been heavily oversold.

For July 2026 (the first month of FY27), the business provided a sales update showing total sales dropped 0.5% for JB Hi-Fi Australia and declined 1.7% for The Good Guys. Positively, JB Hi-Fi New Zealand’s sales growth was 20.9%.

At this stage, sales are only slightly down in Australia.

I believe JB Hi-Fi Australia is well-placed to serve customers with its scale benefits, very competitively priced products, a wide product range, a productive sales floor, and an expanding network of locations in Australia and New Zealand.  

Using the projection on CommSec, the JB Hi-Fi share price is valued at under 15 times FY27’s estimated earnings, with earnings growth projected in FY28 and FY29. That makes it look like a cheap ASX share to me.

The post 2 cheap ASX shares near 52-week lows I’d buy today appeared first on The Motley Fool Australia.

More reading

• ASX retail shares are down 13% in 2026. Here’s what Morgan Stanley is worried about
• 3 ASX dividend stocks to provide passive income through retirement 
• JB Hi-Fi vs Harvey Norman: Which dividend stock wins?
• Here are the top 10 ASX 200 shares today
• 2 ASX blue-chip shares offering big dividend yields

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares have weakened by almost 1% over the past 12 months.

Last week, the market edged lower on growing expectations of another interest rate hike due to stubborn inflation.

Meanwhile, here are some new ratings from the experts.

Orica Ltd (ASX: ORI)

The Orica share price is up 5.7% over 12 months. 

Ord Minnett has a buy rating on this ASX 200 materials share. 

The broker said: 

NaCN [sodium cyanide] is a critical reagent used in gold extraction, and the two largest global producers, Orica and Draslovka, have both indicated their production capacity is fully committed.

With supply effectively sold out, pricing power is improving, as evidenced by recent Australian trade data.

In addition, NaCN costs have not increased at the same pace as broader mining costs despite being an essential input and the gold miners enjoying elevated profitability from strong gold prices. This suggests further pricing upside may be achievable.

Stronger NaCN pricing and improved plant utilisation could drive returns in ORI’s chemicals division back towards historical levels (before the acquisition of Cyanco in 2024) and closer to the company’s broader target range of 13%– 15%. 

BHP Group Ltd (ASX: BHP)

The BHP share price has soared 53% over 12 months. 

Dylan Evans from Catapult Wealth has a hold rating on this ASX 200 mining share. 

Evans said (courtesy The Bull): 

The global miner’s full year results were impressive, with the company increasing revenue and profit.

Growth was driven by the copper division, which is now the primary revenue generator for BHP.

As a result, future earnings will be influenced by the copper price, but the price should be underpinned by several long term themes, including electrification and growing digital infrastructure.

BHP is a core holding. However, the share price has risen substantially in the past 12 months to the point where it can appear expensive.

GQG Partners Inc (ASX: GQG)

The GQG Partners share price has tumbled 37% over 12 months. 

Andrew Wielandt from DP Wealth Advisory has a sell rating on this ASX 200 financial share. 

Wielandt said: 

GQG is a global active fund manager with a diversified range of equity strategies. However, total funds under management of $US149.2 billion at August 31, 2026 had fallen from $US156.4 billion at July 31, 2026.

Total funds under management are also down $US14.7 billion between December 31, 2025 and August 31, 2026.

Outflows create uncertainty about the sustainability of earnings and income.

Until investment performance and funds under management stabilise or tick up, we retain a sell recommendation on GQG.

The post Buy, hold, sell: Orica, GQG Partners, BHP shares appeared first on The Motley Fool Australia.

More reading

• This ASX 200 stock just received a fresh buy rating and is tipped to climb 15%
• If I invest $15,000 in BHP shares, how much passive income will I receive in 2027?
• Copper has overtaken iron ore – Here are the top copper shares to target
• Bought $10,000 worth of BHP shares 5 years ago? Guess how much passive income you’ve already earned
• Are BHP, CBA, and CSL shares top buys?

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group and Gqg Partners. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Perpetual Ltd (ASX: PPT) share price is in focus after the company rejected a further revised takeover proposal from EQT and confirmed the end of discussions. The $22.50 per share proposal was deemed by the board to undervalue Perpetual and carried too much execution risk.

What did Perpetual report?

• Rejected a further revised, non-binding buyout offer from EQT at $22.50 per share.
• Proposal included the option for a permitted dividend of up to $0.60 per share for 1H27.
• Board maintained its view that the offer undervalued the company.
• Sale of Wealth Management business remains on track for completion in Q4 FY26.
• Expected move to a net cash position after the sale, offering increased financial flexibility.

What else do investors need to know?

Perpetual says its engagement process with EQT has now concluded, as the latest proposal was described as “best and final” in the absence of competing offers. Shareholders are not required to take any action in response to this announcement.

The board also reiterated that the planned sale of its Wealth Management arm is proceeding as expected, with completion likely by the end of 2026. This sale is anticipated to enhance Perpetual’s financial position and allow more capital management initiatives in the future.

What’s next for Perpetual?

With the EQT engagement process now closed, Perpetual is focused on its core Asset Management and Corporate Trust businesses. Management highlights a continued commitment to delivering sustainable long-term value to shareholders.

Once the Wealth Management business sale wraps up, Perpetual expects to be in a net cash position, providing room to consider additional capital management options alongside dividends.

Perpetual share price snapshot

Over the past 12 months, Perpetual shares have risen 3%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has declined 1% over the same period.

View Original Announcement

The post Perpetual rejects EQT’s final offer and confirms asset sale plans appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• 5 things to watch on the ASX 200 on Thursday
• 40 ASX shares with ex-dividend dates next week
• Here are the top 10 ASX 200 shares today
• Perpetual posts higher FY26 profit and readies for business sale

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

S&P/ASX 200 Index (ASX: XJO) stock Orica Ltd (ASX: ORI) has slowly climbed back from yearly lows hit in March of this year. 

Since that time, its share price is up 20%.

The company manufactures, distributes, and sells commercial blasting systems, explosives, and mining and tunnelling support systems to the mining industry, as well as various chemical products and services in Australia, Canada, the US, and internationally.

Investor concerns

Lately, there has been concern surrounding the company’s North American ammonium nitrate (AN) supply arrangements. 

This has come following the termination of a key contract with CF Industries (NYSE: CF), which supplied around half of the company’s North American blasting business. 

This comes at a time when the AN supply and demand conditions in the US have tightened. 

Subsequently, this could make it more difficult for Orica to secure new contracts on attractive terms.

Why the concerns may be overblown

However, the team at Ord Minnett appear less concerned. 

The broker said the North American blasting business generated only about 10% of Orica’s FY25 operating profit (EBIT).

And the part connected to the CF Industries contract was only a portion of that.

So, even if this business becomes less profitable, the overall impact on Orica could be manageable rather than disastrous.

Orica is also looking at ways to reduce costs in this division, which could help protect its profit margins.

There is another, potentially more important story.

Orica also produces sodium cyanide (NaCN).

Sodium cyanide is a chemical that is very important for extracting gold from ore.

Demand for this chemical is strong, and supply is tight.

The two biggest producers, one of which is Orica, have said their production capacity is essentially fully booked.

Target price intact 

The team at Ord Minnett said stronger NaCN pricing and improved plant utilisation could drive returns in the company’s chemicals division back towards historical levels (before the acquisition of Cyanco in 2024) and closer to the company’s broader target range of 13% to 15%. 

We increase our earnings forecasts for the chemicals segment to capture the stronger market fundamentals in NaCN. However, this has been more than offset by a stronger Australian dollar since our last note. Consequently, our EPS estimates are revised down by 1.9%, 2.9%, and 3.3% in FY26, FY27, and FY28, respectively. Our target price of $26 is unchanged.

This ASX 200 stock closed trading last week at $22.61. 

Based on the retained price target from Ord Minnett, there is 15% upside for this ASX 200 company. 

The post This ASX 200 stock just received a fresh buy rating and is tipped to climb 15% appeared first on The Motley Fool Australia.

More reading

• Buy, hold, sell: Orica, GQG Partners, BHP shares
• UBS names its 10 top ASX picks for the next 3-6 months
• ASX 200 mining shares outperform in final week of earnings season

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Ramelius Resources Ltd (ASX: RMS) share price is in focus after the gold miner upgraded its FY30 production outlook and released new FY27 guidance, flagging production growth of up to 610,000 ounces by 2030 and an 11% lift on its October 2025 plan.

What did Ramelius Resources report?

• FY30 gold production target upgraded to 560,000–610,000 ounces at an AISC of A$2,100–2,400/oz (11% increase)
• FY27 gold production guidance: 205,000–225,000 ounces at an AISC of A$2,150–2,350/oz
• FY27 growth capital expenditure: A$480–570 million; Mt Magnet plant expansion costs increased (now A$280 million)
• Sale of Edna May hub delivered A$210 million in cash and A$90 million in Forrestania Resource Limited shares
• Current cash, gold and investments exceed A$1 billion

What else do investors need to know?

Ramelius’ production targets are underpinned by expanded operations at Mt Magnet, discoveries at Galaxy and Cue, and development of Rebecca-Roe. Enhanced capital outlays reflect capacity upgrades, infrastructure to future-proof operations, and inflationary impacts.

The company’s outlook assumes a higher gold price (A$5,500/oz) and cost base reflecting sector-wide pressures, but management expects to maintain one of the lowest cost positions among ASX gold miners. The recently appointed EPC contractor, Primero, will deliver a new 3Mtpa processing circuit at Mt Magnet, facilitating future production growth.

What did Ramelius Resources management say?

Managing Director Mark Zeptner said:

We are continuing to systematically unlock the full potential of our Top Tier Mt Magnet hub while de-risking Rebecca-Roe through permitting progress and advanced design work. We expect to maintain our sector-leading AISC position, despite the cost pressures being felt by all gold miners, while delivering a 205% increase in production by FY30… Our targeted exploration strategy, combined with operational and technical expertise, has driven an 11 percent uplift in our FY30 production outlook to more than 600,000 ounces, reaffirming our position as Australia’s standout gold growth story, underpinned by a long term resilient low-cost advantage… These commitments are consistent with our delivery philosophy. FY26 marks our sixth consecutive year of meeting market guidance – demonstrating the discipline and reliability of our operating model. We remain focused on organic growth through investing in exploration and optimisation of existing infrastructure, an approach that we believe will result in superior returns for our shareholders.

What’s next for Ramelius Resources?

Ramelius is pushing ahead with growth plans at Mt Magnet, aiming for a steady-state run rate of 4.3Mtpa in March 2028 and a Life-of-Mine to 2043. The Rebecca-Roe project is advancing through final permitting, with early works capital brought forward to FY27.

The business remains focused on organic growth and ramping up production with a pipeline of resource definition and mine expansion projects, while maintaining a capital-efficient approach and strong balance sheet.

Ramelius Resources share price snapshot

Over the past 12 months, Ramelius Resources shares have declined 3%, trailing the S&P/ASX 200 Index (ASX: XJO), which has fallen 1% over the same period.

View Original Announcement

The post Ramelius Resources boosts production outlook and sets new FY27 guidance appeared first on The Motley Fool Australia.

More reading

• 7 ASX 200 shares with reaffirmed buy ratings this week
• Buy, hold, sell: James Hardie, REA Group, and Ramelius shares
• 3 ASX 200 shares tipped by experts to jump 30% to 62%
• Which ASX gold company is Morgans’ preferred mid cap buy?
• 33 ASX shares going ex-dividend next week

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The average annual return for the ASX share market over the long-term has been approximately 10%. It has been closer to 9% per year for the S&P/ASX 300 Index (ASX: XKO) in the last decade or so.

If any individual ASX share can deliver a double-digit return, there’s a good chance that it’ll be a market-beating return.

There are a few ASX stocks that expert analysts think could deliver enormous returns over the next year. Of course, that’s not a guaranteed return, but it can show how undervalued analysts think these ASX shares are. Let’s look at two potential winners.

Hansen Technologies Ltd (ASX: HSN)

Hansen describes itself as a leading global provider of software and services to the energy and utilities, and communications and media industries. It has customers in more than 80 countries.

The ASX share’s software enables customers to create, sell and deliver new products and services, manage and analyse customer data, and control critical revenue management and customer support processes. In other words, its customers couldn’t run the administration side of their business without Hansen’s software.

FY26 was a solid year of profit growth.

Operating revenue fell 1.5% due to its revenue ‘mix’, including lower licence fees and foreign exchange headwinds. Within that total, support and maintenance revenue grew 13.4% to $230.3 million.

The company also reported 7.2% growth in underlying operating profit (EBITDA) to $119.6 million and 22.5% growth in underlying net profit after tax (NPAT), driven by cost discipline and AI-driven productivity gains.

FY27 revenue is expected to be stable, with recurring support and revenue maintenance to grow between 6% and 8%. The underlying EBITDA margin is expected to exceed 26% – likely lower than FY26’s figure – due to reduced licence revenue and continued investment in AI capabilities, product investment and customer-led development opportunities.

It’s down 25% after revealing its FY26 result, but analysts think there’s a strong bounce back ahead. Hansen said it expects revenue growth in FY28 and the underlying EBITDA margin will return to its target of 30% or more.

According to CMC Invest, analysts have issued seven ratings on the business in the last three months: six buy and one sell. The average price target is $5.42, implying a possible rise of 70% over the next 12 months – that would be significantly higher than where it traded just before it reported FY26.

Nextdc Ltd (ASX: NXT)

Another ASX share worth looking at, according to expert analysts, is Nextdc. It’s a data centre developer and owner, with facilities in each major Australian mainland city, as well as multiple regional hubs.

It also has a growing international presence, with projects proposed in Bangkok, Kuala Lumpur, Singapore and Tokyo.

If you haven’t already seen the company’s FY26 result, I’m sure you won’t be surprised to learn that its revenue and operating profit (EBITDA) rose, while the underlying net loss, depreciation expense and capital expenditure also increased as it heavily invests.

FY26 revenue grew 16% to $496.5 million, while underlying operating profit (EBITDA) increased 15% to $248.8 million.

However, excluding positive property revaluations and a tax benefit (which I’d describe as non-operational items), it would have registered a net loss of $103.9 million – a worsening of 71.7%. Capital expenditure increased 100% to $3.4 billion, and the depreciation and amortisation expense grew 26% to $262.5 million.

In FY27, it expects revenue to grow at least 52%, underlying EBITDA to grow at least 55% and capital expenditure to grow at least 55%.

According to CMC Invest, the business has received nine ratings in the last three months. Eight of those ratings were a buy, and one was a hold. The average price target of $19.61 implies a possible rise of 72% over the next year.

The post 2 ASX shares tipped to surge 70% or more in the next 12 months appeared first on The Motley Fool Australia.

More reading

• Goodman Group vs Nextdc: Which stock is the better buy today?
• Nextdc vs Megaport: Which ASX tech growth share comes out on top?
• 2 ASX 200 shares tipped by brokers to return 73% and 83%
• Down 32%: 3 reasons to buy the BIG dip in NextDC shares today
• Experts name 3 top ASX shares to buy this week

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Telix Pharmaceuticals Ltd (ASX: TLX) share price is in focus today after announcing a merger with ITM Isotope Technologies Munich SE, a global leader in therapeutic radioisotopes. The deal could create a radiopharmaceutical powerhouse, with combined estimated 2026 revenue over US$1.3 billion and deeper supply chain security for Telix’s growing pipeline.

What did Telix Pharmaceuticals report?

• Strategic agreement to acquire 100% of ITM for US$1.65 billion upfront (cash-free/debt-free)
• Post-adjustments, ~US$1.25 billion in Telix shares to ITM shareholders, plus up to US$700 million in milestone payments
• Pro forma combined revenue projected at over US$1.3 billion for 2026
• ITM achieved US$273 million revenue in 2025, with a 40% CAGR from 2021–2025
• Combined group expected to generate positive EBITDA from 2027 onwards

What else do investors need to know?

The merger positions Telix as a vertically integrated leader, with capabilities across radioisotope production, global manufacturing, and therapeutic development. ITM brings expertise in commercial-scale isotope production, including lutetium-177, actinium-225, and terbium-161, and serves over 65 countries.

ITM’s late-stage pipeline includes ITM-11, a novel candidate for treating neuroendocrine tumours, which has completed a Phase 3 trial. This potentially accelerates Telix’s entry into established commercial markets and complements its existing precision medicine platform.

The transaction is subject to shareholder and regulatory approval, with closing expected by the end of FY2026. Following completion, Telix shareholders will own about 76.3% of the combined group, and ITM shareholders the remaining 23.7%.

What did Telix Pharmaceuticals management say?

Telix Managing Director and Group CEO, Dr. Christian Behrenbruch, said:

This merger positions Telix at the forefront of the consolidation that is occurring as the industry matures. ITM is the leader in radioisotope production, with deep scientific expertise and a track record of value-adding innovation. We have enjoyed a close working relationship with ITM for many years and there is strong management alignment for the rationale behind this transaction. By combining our complementary strengths, we will create a company with commercial scale, world-leading supply and the most exciting theranostic drug portfolio in the sector. Importantly, this combination further expands our late-stage therapeutic pipeline with two completed Phase 3 trials and deepens radioisotope security, while bringing together the mission-critical capabilities needed to deliver radiopharmaceutical treatments to patients around the world.

What’s next for Telix Pharmaceuticals?

Telix expects the merger to drive new growth opportunities, deepen its global supply chain, and enhance its ability to deliver innovative cancer therapies. The launch of ITM-11, if approved, could open up additional high-margin revenues in targeted radionuclide therapy markets.

Management anticipates further cost savings, manufacturing efficiencies, and synergy benefits post-merger. An extraordinary general meeting is planned for November 2026 to seek shareholder approval.

Telix Pharmaceuticals share price snapshot

Over the past 12 months, Telix shares have risen 19%, outpacing the S&P/ASX 200 Index (ASX: XJO), which has declined 1% over the same period.

View Original Announcement

The post Telix Pharmaceuticals: ITM merger builds a sector leader appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• ASX 200 healthcare shares lead a weaker market amid 82% chance of a rate hike
• Forget CSL shares, I’d buy this ASX biotech stock instead
• 4DMedical vs Telix Pharmaceuticals: ASX health tech share showdown
• Are Telix shares a buy after its big US FDA news?

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

It has been a tough 12 months for ASX financials stock Regal Partners Ltd (ASX: RPL). 

The specialist alternative investment manager has seen its share price fall more than 30% year to date. 

However, a new report from Ord Minnett points to a major rebound over the next year. 

The company manages a range of investment strategies covering hedge funds, growth equity, real & natural assets and credit & royalties on behalf of institutions, family offices, charitable groups and private investors.

Not just a dividend stock 

In recent months, this ASX financials stock has been highlighted for its generous dividend yield – and for good reason. 

It currently offers a very healthy dividend yield of 11.1%, after more than doubling its net profit over the past financial year.

However, recent share price weakness now makes it an attractive growth option as well. 

According to Ord Minnett, it delivered a strong first-half FY26 result (1H26), though attention focused mainly on the announced transition to retirement of founder and portfolio manager Philip King. 

Mr King is responsible for approximately 16% of RPL’s funds under management (FUM), or $3.4 billion, and will remain in his current roles until at least 30 June 2027. The extended handover period should help support continuity. RPL declared a fully franked interim dividend of 12 cents per share (cps) which was double last year’s interim. Financially, the result was robust. Normalised net profit after tax reached $93 million (guidance was for at least $90 million), more than double the prior corresponding period, and 3% ahead of consensus.

Flows remain strong

Ord Minnett also highlighted the standout contributor during the most recent half was performance fees which came-in at $119 million. 

This was above guidance for at least $115 million, and significantly higher than the $42 million generated in the first-half of FY25. “Performance fees may moderate in the second-half of FY26 given the amount of FUM that is at, or within, 5% of its high-water mark, has fallen by $1.1 billion in the six months to 30 June 2026.

This has likely declined further in July given softer investment returns from a range of long/short strategies. Flows remain strong. Net inflows totalled $300 million in July, with additional inflows during August across credit and listed investment company products. This momentum has prompted us to lift our expectations for CY26 net inflows to $2.2 billion, ahead of management’s guidance of $2 billion.

Big upside for ASX financials stock

Based on this guidance, Ord Minnett slightly lowered its price target on this ASX financials stock. However, significant upside remains. 

The broker now has a price target of $4.90 (previously $5.40). 

We maintain a Buy recommendation. Despite the leadership transition risk, RPL is trading on an attractive FY27 price to earnings multiple of circa 8x, and on our numbers, offers around 14% per annum growth in EPS over FY26–29.

From current levels, this indicates 118% upside potential. 

The post Ord Minnett tips this ASX financials stock to double within the next 12 months  appeared first on The Motley Fool Australia.

More reading

• How much superannuation do I need to earn $70,000 per year in passive income?
• 3 ASX shares with dividend yields of between 6% and 11%
• How much superannuation do I need to earn $80,000 per year in passive income?
• How much is needed in superannuation for $3,000 in weekly passive income?
• Attention! This ASX 300 stock could be set to rise 50% and has a 7% yield

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.